Expression of FAS/APO 1/CD 95 in thyroid tumors.
Using immunohistochemistry, Fas/Apo-1 protein expression was investigated in thyroid cancers of 67 patients. Thyroid biopsies from twenty eight patients with benign thyroid diseases were also examined. The patients with thyroid cancer manifested a variable histology of the cancer, including 14 patients with follicular carcinoma, 48 with papillary carcinoma, 5 patients with medullary carcinoma. The benign thyroid disease involved nodular goitre in 11 patients and follicular adenoma in other 17 patients. The study aimed at examining immunohistochemical expression of Fas protein in order to determine whether the level of its expression correlated with histological diagnosis. In individual patients Fas expression was more prevalent in thyroid carcinomas as compared to benign tumors (p=0.001). A marked increase in Fas expression was found in papillary carcinoma, as compared to follicular and medullary carcinomas (p=0.02). In conclusion, Fas was significantly more frequently overexpressed in thyroid cancer, indicating its role in thyroid tumorigenesis.
Rzeszutko
Marta
M
Department of Pathological Anatomy, University Medical School, Wrocław, Poland. piotr@hist.am.wroc.pl
Rzeszutko
Wojciech
W
Dziegiel
Piotr
P
Balcerzak
Waldemar
W
Kaliszewski
Krzysztof
K
Bolanowski
Marek
M
D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D005260:Female; D006044:Goiter, Nodular / Q000473:pathology; D006801:Humans; D008297:Male; D008875:Middle Aged; D013964:Thyroid Neoplasms / Q000378:metabolism* / Q000473:pathology; D019014:fas Receptor / Q000378:metabolism*
D019014:fas Receptor